Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature?

Dr Camille Ettelaie C.Ettelaie@hull.ac.uk
Lecturer

Professor Anthony Maraveyas

TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research Sep 1, 2017 - Dec 31, 2026
The death rate is higher in Yorkshire than the rest of England resulting in about 200 extra deaths each year of which more than half are in Hull. There are other significant cancer outcome inequalities between different groups; for example poorer pe... Read More about TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research.

A study of the incorporation and release of tissue factor as cancer cell-derived microparticles. Aug 1, 2014 - Jul 31, 2017

Differentiating the malignant potential of pancreatic cysts Oct 1, 2017 - Dec 31, 2022
The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pan... Read More about Differentiating the malignant potential of pancreatic cysts.

Bridging grant for Research PhD student Nov 1, 2017 - Apr 18, 2018
The fund is to support the stipend and some of the fees incurred to bridge the funding for the PhD student.

Consumables for PhD project Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions (TEM-PAC) Feb 1, 2021 - Jul 31, 2026